Zur Kurzanzeige

dc.creatorEfthymiou G., Liaskos C., Simopoulou T., Marou E., Patrikiou E., Scheper T., Meyer W., Daoussis D., Sakkas L.I., Bogdanos D.P.en
dc.date.accessioned2023-01-31T07:37:07Z
dc.date.available2023-01-31T07:37:07Z
dc.date.issued2020
dc.identifier10.1007/s12026-020-09124-w
dc.identifier.issn0257277X
dc.identifier.urihttp://hdl.handle.net/11615/71284
dc.description.abstractHelicobacter pylori (Hp) is a likely trigger of systemic sclerosis (SSc), but systemic antigen-specific antibody (Ab) responses in a well-defined cohort of SSc patients have not been thoroughly assessed. Line immunoassay and immunoblotting testing Abs against 15 Hp antigens were performed in 91 SSc patients and 59 demographically matched healthy controls (HCs). Results were validated in an independent cohort of 35 SSc patients. Anti-Hp positivity was detected in 67% SSc patients vs 76.3% HCs. Among anti-Hp (+) individuals, anti-p67-FSH was less frequent in SSc than HCs (p = 0.016), whereas reactivity to the remaining 14 Hp antigens did not differ between patients and HCs. Anti-p67 Abs were less frequent in diffuse cutaneous SSc (dcSSc) compared with HCs (p = 0.018). Anti-p57 and anti-p33 Ab levels were lower in SSc vs HCs (p = 0.007 and p = 0.035, respectively). Anti-p57 and anti-p33 Ab levels were lower in limited cutaneous SSc (lcSSc) (p = 0.010) and dcSSc (p = 0.024), respectively, compared with HCs. Anti-p50 and anti-p17 Ab titers tended to be higher in dcSSc than in lcSSc. Sera from the independent SSc cohort showed comparable results. Anti-VacA Abs were more frequent in pulmonary arterial hypertension (p = 0.042), and anti-p30 Abs were more frequent in calcinosis (p = 0.007), whereas anti-VacA Ab levels were higher in lung fibrosis (p = 0.02). In conclusion, anti-Hp Abs are neither more frequent nor elevated in SSc compared with healthy population, the only exception being the higher frequency and levels of anti-VacA Abs in pulmonary hypertension and lung fibrosis, respectively. These results suggest that Hp is unlikely to be involved in the development of SSc. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.en
dc.language.isoenen
dc.sourceImmunologic Researchen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85083065669&doi=10.1007%2fs12026-020-09124-w&partnerID=40&md5=474d21f6b84983a3bbbae6209e6858b7
dc.subjectbacterial antigenen
dc.subjectbacterium antibodyen
dc.subjectbacterial antigenen
dc.subjectbacterium antibodyen
dc.subjectepitopeen
dc.subjectadulten
dc.subjectageden
dc.subjectantibody responseen
dc.subjectantibody titeren
dc.subjectantigen antibody reactionen
dc.subjectantigen specificityen
dc.subjectArticleen
dc.subjectcalcinosisen
dc.subjectcohort analysisen
dc.subjectcontrolled studyen
dc.subjectfemaleen
dc.subjectHelicobacter pylorien
dc.subjecthumanen
dc.subjecthumoral immunityen
dc.subjectimmunoassayen
dc.subjectimmunoblottingen
dc.subjectline immunoassayen
dc.subjectlung fibrosisen
dc.subjectmajor clinical studyen
dc.subjectmaleen
dc.subjectmiddle ageden
dc.subjectpriority journalen
dc.subjectpulmonary hypertensionen
dc.subjectseroprevalenceen
dc.subjectsystemic sclerosisen
dc.subjectHelicobacter infectionen
dc.subjectHelicobacter pylorien
dc.subjecthumoral immunityen
dc.subjectimmunologyen
dc.subjectmetabolismen
dc.subjectphysiologyen
dc.subjectsystemic sclerosisen
dc.subjectvery elderlyen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectAntibodies, Bacterialen
dc.subjectAntigens, Bacterialen
dc.subjectCohort Studiesen
dc.subjectEpitopesen
dc.subjectFemaleen
dc.subjectHelicobacter Infectionsen
dc.subjectHelicobacter pylorien
dc.subjectHumansen
dc.subjectImmunity, Humoralen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectScleroderma, Systemicen
dc.subjectSpringeren
dc.titleAntigen-specific humoral responses against Helicobacter pylori in patients with systemic sclerosisen
dc.typejournalArticleen


Dateien zu dieser Ressource

DateienGrößeFormatAnzeige

Zu diesem Dokument gibt es keine Dateien.

Das Dokument erscheint in:

Zur Kurzanzeige